Stathmin test to guide chemotherapy for oral cancer
Part of Cancer clinical trials.
This Phase 2 trial uses a lab test called “Stathmin” to help predict who may benefit from a specific chemotherapy plan for squamous cell carcinoma of the mouth. It aims to improve treatment choice by linking Stathmin levels to how well chemotherapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed squamous cell carcinoma of the mouth (including tongue, gums, inner cheek, floor of mouth, palate, or back of the jaw).
- You are age 18 to 75, and your general health (Karnofsky score) is greater than 70.
- Your tumor test shows a LOW level of Stathmin 1 (checked by a lab stain test on tissue).
- Cancer is stage III or IVA, and you do NOT have cancer spread to distant organs (metastasis) or another active cancer.
- You must meet key blood and organ requirements (blood counts not too low, and liver/kidney tests within limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
Hear when a new Neoplasm Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.